Thomas Flaten
Stock Analyst at Lake Street
(1.94)
# 2,824
Out of 5,182 analysts
43
Total ratings
33.33%
Success rate
-2.6%
Average return
Main Sectors:
Stocks Rated by Thomas Flaten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASRT Assertio Holdings | Downgrades: Hold | $45 → $18 | $18.47 | -2.54% | 4 | Apr 9, 2026 | |
| EVAX Evaxion | Maintains: Buy | $11 → $9 | $4.50 | +100.22% | 4 | Mar 9, 2026 | |
| IMDX Insight Molecular Diagnostics | Maintains: Buy | $8 → $12 | $4.18 | +187.08% | 1 | Feb 17, 2026 | |
| CSTL Castle Biosciences | Maintains: Buy | $35 → $52 | $24.81 | +109.59% | 7 | Jan 12, 2026 | |
| PTHS Pelthos Therapeutics | Initiates: Buy | $50 | $25.00 | +100.00% | 1 | Dec 3, 2025 | |
| CNTB Connect Biopharma Holdings | Initiates: Buy | $9 | $2.47 | +264.37% | 1 | Dec 1, 2025 | |
| MDXH MDxHealth | Maintains: Buy | $7 → $9 | $2.06 | +336.89% | 1 | Nov 13, 2025 | |
| HROW Harrow | Maintains: Buy | $42 → $70 | $40.90 | +71.15% | 1 | Sep 29, 2025 | |
| DERM Journey Medical | Maintains: Buy | $9 → $13 | $5.20 | +150.00% | 2 | Aug 13, 2025 | |
| RPID Rapid Micro Biosystems | Initiates: Buy | $8 | $2.53 | +216.21% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $14 | $6.18 | +126.54% | 2 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.63 | +204.18% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $40 | $11.08 | +261.01% | 1 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $17 → $9 | $9.60 | -6.25% | 5 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $4.20 | +90.48% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $9 | $5.78 | +55.71% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $11 | $4.38 | +151.14% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $25 | $21.21 | +17.87% | 2 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14,400 → $1,440 | $0.39 | +370,079.95% | 2 | Nov 17, 2022 |
Assertio Holdings
Apr 9, 2026
Downgrades: Hold
Price Target: $45 → $18
Current: $18.47
Upside: -2.54%
Evaxion
Mar 9, 2026
Maintains: Buy
Price Target: $11 → $9
Current: $4.50
Upside: +100.22%
Insight Molecular Diagnostics
Feb 17, 2026
Maintains: Buy
Price Target: $8 → $12
Current: $4.18
Upside: +187.08%
Castle Biosciences
Jan 12, 2026
Maintains: Buy
Price Target: $35 → $52
Current: $24.81
Upside: +109.59%
Pelthos Therapeutics
Dec 3, 2025
Initiates: Buy
Price Target: $50
Current: $25.00
Upside: +100.00%
Connect Biopharma Holdings
Dec 1, 2025
Initiates: Buy
Price Target: $9
Current: $2.47
Upside: +264.37%
MDxHealth
Nov 13, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $2.06
Upside: +336.89%
Harrow
Sep 29, 2025
Maintains: Buy
Price Target: $42 → $70
Current: $40.90
Upside: +71.15%
Journey Medical
Aug 13, 2025
Maintains: Buy
Price Target: $9 → $13
Current: $5.20
Upside: +150.00%
Rapid Micro Biosystems
Jul 28, 2025
Initiates: Buy
Price Target: $8
Current: $2.53
Upside: +216.21%
Jul 18, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $6.18
Upside: +126.54%
Jul 1, 2025
Initiates: Buy
Price Target: $8
Current: $2.63
Upside: +204.18%
May 14, 2025
Maintains: Buy
Price Target: $60 → $40
Current: $11.08
Upside: +261.01%
Mar 20, 2025
Downgrades: Hold
Price Target: $17 → $9
Current: $9.60
Upside: -6.25%
Mar 7, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $4.20
Upside: +90.48%
Jan 8, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $5.78
Upside: +55.71%
Mar 5, 2024
Maintains: Buy
Price Target: $19 → $11
Current: $4.38
Upside: +151.14%
Aug 9, 2023
Maintains: Buy
Price Target: $34 → $25
Current: $21.21
Upside: +17.87%
Nov 17, 2022
Maintains: Buy
Price Target: $14,400 → $1,440
Current: $0.39
Upside: +370,079.95%